Search Results - "Rubbert-Roth, Andrea"

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.

Authors: Rubbert-Roth, Andrea Kato, Koji Haraoui, Boulos et al.

Source: Rheumatology & Therapy. Oct2024, Vol. 11 Issue 5, p1197-1215. 19p.

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Authors: Rubbert-Roth, Andrea Kakehasi, Adriana M. Takeuchi, Tsutomu et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p97-112. 16p.

Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies.

Authors: Kiltz, Uta Chen, Yi-Ming Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. May2026, p1-32. 32p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Bei Diagnostik und medikamentöser Therapie der entzündlichen Arthritiden gibt es geschlechtsspezifische Unterschiede.

Authors: Rubbert-Roth, Andrea¹ (AUTHOR)

Source: Kompass Autoimmun. 2023, Vol. 5 Issue 3, p101-103. 3p.

Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.

Authors: Rehberg, Markus Giegerich, Clemens Praestgaard, Amy et al.

Source: Rheumatology & Therapy. Dec2021, Vol. 8 Issue 4, p1921-1922. 2p.

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).

Authors: Koehm, Michaela Foldenauer, Ann C. Rossmanith, Tanja et al.

Source: Journal of Clinical Medicine. Dec2022, Vol. 11 Issue 24, p7316. 13p.

Worse cardiovascular and renal outcome in male SLE patients.

Authors: Mihailovic, Jelena Ribi, Camillo Chizzolini, Carlo et al.

Source: Scientific Reports. 10/30/2023, Vol. 13 Issue 1, p1-12. 12p.

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Authors: Rubbert-Roth, Andrea Furst, Daniel E. Nebesky, Jan Michael et al.

Source: Rheumatology & Therapy. Jun2018, Vol. 5 Issue 1, p21-42. 22p.

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Authors: Taylor, Peter C. Chen, Yun-Fei Pope, Janet et al.

Source: Rheumatology & Therapy. Apr2023, Vol. 10 Issue 2, p463-476. 14p.

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Authors: Burmester, Gerd R. Winthrop, Kevin Blanco, Ricardo et al.

Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.

Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1?

Authors: Vuilleumier, Nicolas Pagano, Sabrina Ludewig, Burkhard et al.

Source: European Journal of Clinical Investigation. Feb2022, Vol. 52 Issue 2, p1-6. 6p.

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.

Authors: Rehberg, Markus Giegerich, Clemens Praestgaard, Amy et al.

Source: Rheumatology & Therapy. Dec2021, Vol. 8 Issue 4, p1661-1675. 15p.

Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients.

Authors: Grajewski, Rafael S. Caramoy, Albert Frank, Konrad F. et al.

Source: Ocular Immunology & Inflammation. Aug2015, Vol. 23 Issue 4, p346-352. 7p.

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.

Authors: Adasme, Melissa F. Parisi, Daniele Van Belle, Kristien et al.

Source: PLoS ONE. 5/27/2020, Vol. 15 Issue 5, p1-26. 26p.

Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases.

Authors: Schultz, Olaf Oberhauser, Frank Saech, Jasemine et al.

Source: PLoS ONE. 2010, Vol. 5 Issue 12, p1-7. 7p.

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.

Authors: Mueller, Ruediger B. Hasler, Caroline Popp, Florian et al.

Source: Journal of Clinical Medicine. Oct2019, Vol. 8 Issue 10, p1548. 1p.

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.

Authors: Raptis CE Berger CT Ciurea A et al.

Source: Frontiers in immunology [Front Immunol] 2022 Oct 13; Vol. 13, pp. 1016927. Date of Electronic Publication: 2022 Oct 13 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR): reply.

Authors: Rubbert-Roth, Andrea Tak, Paul P. Zerbini, Cristiano et al.

Source: Rheumatology Mar2011; Vol. 50 (3).

Journal Info: Publisher: Oxford University Press / USA ISSN: 1462-0324

Abstract Supplement ACR Convergence 2023.

Source: Arthritis & rheumatology Oct2023 Supplement; Vol. 75.

Journal Info: Publisher: Wiley-Blackwell ISSN: 2326-5191